Proactive Investors - Run By Investors For Investors

ANGLE liquid biopsy yields predictive results in colorectal cancer

The results of a study are to be presented to the prestigious American Society of Clinical Oncology in Chicago
ANGLE liquid biopsy yields predictive results in colorectal cancer
Small samples of blood are able to yield tell-tale signs of cancer

Med-tech firm ANGLE PLC (LON:AGL, OTCQX:ANPCY) has uncovered another potential use of its liquid biopsy system building on the success it has already had isolating and identifying tell-tale signs of breast, head and neck cancers.

The results of a study to be presented to the prestigious American Society of Clinical Oncology in Chicago point to a potential use in the colorectal cancer.

Researchers at the University of Texas MD Anderson Cancer Center used ANGLE’s Parsortix system to harvest circulating tumour cells in patients with the disease.

What they were looking for meEGFR biomarkers within the cells. It is thought patients with said genetic characteristic respond less well to a form of treatment called an EGFR inhibitor.

The MD Anderson study found those with the markers had shorter progression-free survival rates than those without.

Growing body of evidence

"This colorectal cancer study adds to the body of evidence driving adoption of Parsortix in the fast growing liquid biopsy market,” said ANGLE chief executive Andrew Newland.

“The ability to assess the patient's likely response to a particular drug as a companion diagnostic is a key element in the drive to provide precision medicine for patients saving money and improving treatment."

ANGLE invented and developed the revolutionary Parsortix system, which can detect the early signs of cancer from small samples of blood by identifying the presence of tiny circulating tumour cells.

Parsortix is the centre-piece in two clinical studies in ovarian cancer: ANG-001 in Europe (200 patients) and ANG-003 in the United States (200 patients).

The headline data following a statistical evaluation of the predictive power of the device should be available sometime this quarter, the firm said last month.

ANG-002, assessing Parsortix’s role in detecting metastatic breast cancer, remains on track for completion by the end of the calendar year, it added.  

WATCH: Our last chat with the boss

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use